No connection

Search Results

AHG vs LLY

AHG
Akso Health Group
BEARISH
Price
$2.50
Market Cap
$2.14B
Sector
Healthcare
AI Confidence
85%
LLY
Eli Lilly and Company
NEUTRAL
Price
$958.65
Market Cap
$858.01B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AHG
--
LLY
41.7
Forward P/E
AHG
--
LLY
22.78
P/B Ratio
AHG
10.82
LLY
32.33
P/S Ratio
AHG
144.3
LLY
13.16
EV/EBITDA
AHG
-4387.63
LLY
27.08

Profitability

Gross Margin
AHG
1.0%
LLY
83.04%
Operating Margin
AHG
-20.54%
LLY
44.9%
Profit Margin
AHG
0.0%
LLY
31.67%
ROE
AHG
-68.29%
LLY
101.16%
ROA
AHG
-1.42%
LLY
19.41%

Growth

Revenue Growth
AHG
0.9%
LLY
42.6%
Earnings Growth
AHG
--
LLY
51.4%

Financial Health

Debt/Equity
AHG
0.01
LLY
1.65
Current Ratio
AHG
1.53
LLY
1.58
Quick Ratio
AHG
1.19
LLY
0.78

Dividends

Dividend Yield
AHG
--
LLY
0.68%
Payout Ratio
AHG
0.0%
LLY
26.14%

AI Verdict

AHG BEARISH

AHG's Piotroski F-Score of 5/9 indicates a stable but not strong financial position, with significant red flags in profitability and cash flow. The company reports a 0.00% profit margin, negative ROE of -68.29%, and a gross margin of just 1.00%, signaling deep operational inefficiencies. Despite a low debt/equity ratio and decent liquidity, the absence of positive earnings, free cash flow, and a lack of dividend support undermine long-term sustainability. The stock's price performance is driven by speculative momentum rather than fundamentals, with a Price/Sales of 144.30 far exceeding sector averages and no intrinsic value support.

Strengths
Low debt/equity ratio (0.01) indicates minimal financial leverage risk
Current ratio of 1.53 and quick ratio of 1.19 suggest adequate short-term liquidity
Recent price surge (85.2% in 1 week) reflects strong short-term market momentum
Risks
Negative ROE (-68.29%) and ROA (-1.42%) indicate severe capital inefficiency and losses
0.00% profit margin and -20.54% operating margin reveal fundamental business model flaws
No free cash flow or operating cash flow data available, raising liquidity sustainability concerns
LLY NEUTRAL

LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)

Compare Another Pair

AHG vs LLY: Head-to-Head Comparison

This page compares Akso Health Group (AHG) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile